Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study

Table 3 Systemic embolism risk of different lipoprotein (a) levels (mg/dL) in patients with non-valvular atrial fibrillation

Lp(a)	Events, n (%)	Crude model		Model 1		Model 2		Model 3
Lp(a)	Events, n (%)	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Q1 (< 7.1)	14 (0.3)	1.00		1.00		1.00		1.00
Q2 [7.1, 13.4)	37 (0.9)^a	2.68 (1.45, 4.96)	0.002	2.59 (1.40, 4.80)	0.003	2.60 (1.40,4.82)	0.002	2.48 (1.33, 4.61)	0.004
Q3 [13.4, 25.4)	34 (0.8)^b	2.45 (1.31, 4.57)	0.005	2.36 (1.26, 4.40)	0.007	2.39 (1.28, 4.47)	0.006	2.38 (1.27, 4.46)	0.007
Q4 (≥ 25.4)	48 (1.2)^c	3.48 (1.92, 6.32)	< 0.001	3.27 (1.80, 5.95)	< 0.001	3.35 (1.84, 6.09)	< 0.001	3.38 (1.85, 6.19)	< 0.001
P for trend	< 0.001		0.001		0.002		0.001		0.001
Log-Lp(a)		2.66 (1.73, 4.08)	< 0.001	2.54 (1.65, 3.91)	< 0.001	2.59 (1.68, 4.00)	< 0.001	2.78 (1.78, 4.36)	< 0.001

Abbreviations: Lp(a) Lipoprotein(a), Log log-transformed, OR Odds ratio, 95% CI 95% confidence interval
Model 1: adjusted for sex, age, and ethnicity; Model 2: adjusted for CHA₂DS₂-VASc score; Model 3: adjusted for ethnicity, CHA₂DS₂-VASc score, anticoagulants, lipid-lowering medications, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein A1, apolipoprotein B, and red-cell distribution width
^aindicates a significant difference between Q1 and Q2
^bindicates a significant difference between Q1 and Q3
^cindicates a significant difference between Q1 and Q4

ISSN: 1476-511X